Do the equity-efficiency preferences of the Israeli Basket Committee match those of Israeli health policy makers?

Amir Shmueli

Abstract

Background: Prioritization of medical technologies requires a multi-dimensional view. Often, conflicting equity and efficiency criteria should be reconciled. The most dramatic manifestation of such conflict is in the prioritization of new medical technologies asking for public finance performed yearly by the Israeli Basket Committee. The aim of this paper is to compare the revealed preferences of the 2006/7 Basket Committee’s members with the declared preferences of health policy-makers in Israel.

Methods: We compared the ranking of a sample of 18 accepted and 16 rejected technologies evaluated by the 2006/7 Basket Committee with the ranking of these technologies as predicted based on the preferences of Israeli health policy-makers. These preferences were elicited by a recent Discrete Choice Experiment (DCE) which estimated the relative weights of four equity and three efficiency criteria. The candidate technologies were characterized by these seven criteria, and their ranking was determined. A third comparative ranking of these technologies was the efficiency ranking, which is based on international data on cost per QALY gained.

Results: The Committee’s ranking of all technologies show no correspondence with the policy-makers’ ranking. The correlation between the two is negative when only accepted technologies are ranked. The Committee’s ranking is positively correlated with the efficiency ranking, while the health policy-makers’ ranking is not.

Discussion: The Committee appeared to assign to efficiency considerations a higher weight than assigned by health policy-makers. The main explanation is that while policy-makers’ ranking is based on stated preferences, that of the Committee reflects revealed preferences. Real life prioritization, made under a budget constraint, enhances the importance of efficiency considerations at the expense of equity ones.

Conclusions: In order for Israeli health policy to be consistent and well coordinated across policy-makers, some discussions and exchanges are needed, to arrive at a common set of preferences with respect to equity and efficiency considerations.

Keywords: Efficiency, Equity, Policymakers, Health, DCE, Basket Committee, Prioritization

Background

There is a traditional and long-standing tension in economics and public policy between efficiency - defined as the maximization of welfare - and equity, which includes considerations of equality, the distribution of welfare and social justice.

In terms of health policy, the aspiration to efficiency is equivalent to the maximization of health. When health is measured as quality-adjusted life years (QALYs), as is the case in economic assessments of health technologies, efficiency is identified with the maximization of QALYs. However, maximization of health itself does not take into account considerations of equality, justice, medical need, etc. [1]. On the other hand, when health policy is concerned with the needy or poor, some efficiency might have to be given up.

Policy-makers try to reconcile between efficiency and equity considerations when formulating health policy [2]. Such conciliation is particularly difficult in the
prioritization of new medical technologies facing a limited budget, as is the case of the decisions made by the members of the Israeli Basket Committee.

While general guidelines and principles were offered to the members of the Committee [3], their actual decisions were never analysed with respect to the conciliation of equity and efficiency criteria.

The 2006/7 Basket Committee reported not only its inclusion decisions, but also ranked the accepted technologies. An earlier study [4] examined the concordance between this prioritization of technologies and prioritization based on international data on cost per QALY gained by these technologies, the most significant efficiency criterion. The findings indicated that while the concordance is weak and several marked differences exist, the correlation between the two rankings is significantly positive, and in general, the inclusion decisions – as well as the prioritization of the accepted technologies - might be justified on efficiency grounds.

A recent Discrete Choice Experiment (DCE) elicited the declared preferences of Israeli health policy-makers with regard to efficiency and equity considerations. The results indicated that the preferences of Israeli health policy-makers with regard to equity and efficiency criteria are quite balanced. This balance is quite exceptional when comparing the Israeli preferences to those declared by health policy-makers in other countries [5].

Objectives
The objective of this study is to compare the revealed ranking of the technologies evaluated by the 2006/7 Basket Committee's members with the ranking derived from the declared preferences of health policy-makers in Israel.

Methods
A recent DCE estimated the relative weights of equity and efficiency criteria in the preferences of Israeli health policy-makers [5].

The criteria were taken from an international study [6], and were adapted to the Israeli reality. Four equity criteria were used: severity of the disease (measured as less or more than 2 healthy years), age of treated patients (young vs. others and elderly vs. others), and the extent to which the subsidization of the poor is important. The three efficiency criteria included the potential number of beneficiaries (more or less than 100,000), the extent of the health benefits to the patient (less or more than 5 healthy years), and the results of economic assessments (cost per QALY gained is less or more than GNP per capita).

Since national health insurance systems, such as the Israeli one, are based on solidarity and cross-subsidization between the rich/healthy and the sick/poor, the criterion relating to the “subsidization of the poor” was reformulated as “the technology should be financed publicly so that the poor could afford it” (yes or no). The operational definition of affordability was based on actual policy: the monthly copayment ceiling for chronic patients was about 250 NIS in 2006, and we assumed that a monthly cost of a technology - if not financed publicly - of less than 125 NIS is affordable to the poor. This threshold is equivalent to 10% of the Israeli official poverty line in 2006. Consequently, technologies with a monthly cost of use of less than 125 NIS are characterized by “no” for this criterion, and more expensive technologies are characterized by “yes”. In order to explore the effect of the threshold in the criteria “the technology should be financed publicly so that the poor can use it” (125 NIS), we repeated the analysis with a threshold of 250 NIS.

The sample included past and present senior managers from the Ministry of Health, Ministry of Finance, the Sickness Funds, the Israeli Medical Associations, and hospitals’ directors. Sixty-five out of 146 policy-makers completed the survey. Due to technical problems, only 40 of them completed the demographic questions. The survey did not need a Helsinki approval.

The weights of the seven criteria were estimated using DCE methodology by the software 1000Minds. For more details see [5]. Once these weights are known, any technology, characterized by the seven criteria, can be evaluated and assigned a “desirability score”. This score indicates the likelihood that the technology – characterized by its own levels on the criteria, and using the estimated weights of the criteria – is preferred to other technologies (characterized by their own profiles of the criteria's levels).

We focus in this paper on the decisions and prioritization made by the 2006/7 Basket Committee. In addition to deciding which technologies were included in the Basket financed by public funds, the Committee also ranked the accepted technologies.

Using the material presented to the Committee and consultations with physicians, we characterized random samples of 18 accepted technologies and 16 rejected technologies as profiles of the 7 criteria. Each technology was assigned a desirability score, predicted using the estimated weights, and the ranking of the entire set – as well as of the accepted technologies only – resulted. We derived the ranking for the entire sample of Israeli health policy-makers, as well as that for physicians and those who have ever served on the Basket Committee.

Results
The exact definition of the seven criteria and their weights – as well as the total weight of the equity and efficiency criteria – in the selected sub-groups of health policy-makers, are presented in Table 1 (further details on the international comparison can be found in [5]).

The two most important criteria in all sub-groups and in the entire sample are "funding the technology is necessary
Table 1 Relative weights of the equity and efficiency criteria

| Equity criteria                                                                 | Efficiency criteria                  | Efficiency Weight | Equity Weight | Total |
|---------------------------------------------------------------------------------|--------------------------------------|-------------------|--------------|-------|
| Number of respondents                                                           |                                      |                   |              |       |
| The technology is intended for patients suffering from a serious disease (life expectancy is less than 2 healthy years): Yes | The Number of patients requiring the technology: more than 100,000 |                   |              |       |
| The Technology is intended to treat a disease common among children: Yes         | Individual Benefit: addition of more than 5 healthy years |                   |              |       |
| Funding the technology is required so that the poor can use it: Yes             | Cost per Quality Adjusted Life Year: Less than the GNP per capita |                   |              |       |
|                                                                                   |                                      |                   |              |       |
| Physicians                                                                      |                                      |                   |              |       |
| 25                                                                               | 11                                   | 16                | 9            | 20    |
| Non-physicians                                                                  |                                      |                   |              |       |
| 15                                                                               | 8                                    | 15                | 9            | 19    |
| Ever served on Basket Committee                                                 |                                      |                   |              |       |
| 11                                                                               | 9                                    | 15                | 9            | 16    |
| Never did                                                                       |                                      |                   |              |       |
| 29                                                                               | 10                                   | 16                | 9            | 21    |
| Respondents answering the demographic questionnaire                             |                                      |                   |              |       |
| 40                                                                               | 10                                   | 16                | 9            | 20    |
| Respondents not answering the demographic questionnaire                          |                                      |                   |              |       |
| 25                                                                               | 13                                   | 11                | 12           | 17    |
| Total                                                                           |                                      |                   |              |       |
| 65                                                                               | 11                                   | 14                | 10           | 19    |
so that the poor will also be able to use it", clearly an equity
criterion, and "benefit to the individual", a major efficiency
criterion. The criteria whether the technology was intended
primarily for the elderly or to treat a severe disease were
the least important in all subgroups, both of them being
equity criteria.

In the entire sample, the efficiency criteria have a total
weight of 46% and the equity criteria – 54%. Physicians
tend slightly more toward equity criteria (total weight =
56%), and those who have ever served on a Basket Com-
mittee tend more to efficiency criteria (total weight = 51%).

Tables 2 and 3 present side by side four rankings of the
34 technologies evaluated by the Committee (the tech-
nologies appear in the Tables according to their Commit-
tee’s rank), using the two monthly cost thresholds – 125
and 250 NIS respectively. These rankings include the

| Technology          | Committee’s inclusion decision | Rank Basket Committee | Rank survey - Total | Rank survey - Physicians | Rank survey - Members of any Basket Committee | Rank efficiency |
|---------------------|--------------------------------|-----------------------|---------------------|--------------------------|-----------------------------------------------|-----------------|
| Crestor Ezetrol     | YES                            | 1                     | 18                  | 18                       | 15                                            | 12              |
| Atacand Ocsaar Diovan Olmetec | YES    | 2                     | 29                  | 29                       | 25                                            | 3               |
| Lantus Levernir     | YES                            | 3                     | 29                  | 29                       | 25                                            | 5               |
| Apidra Humalog Novorapid | YES   | 4                     | 29                  | 29                       | 25                                            | 9               |
| Bloxatine           | YES                            | 5                     | 15                  | 15                       | 18                                            | 4               |
| Velodopa            | YES                            | 6                     | 15                  | 15                       | 15                                            | 1               |
| Herceptin           | YES                            | 7                     | 11                  | 11                       | 12                                            | 23              |
| Hepsera             | YES                            | 8                     | 3                   | 3                        | 3                                             | 16              |
| Viread              | YES                            | 9                     | 9                   | 9                        | 7                                             | 22              |
| Prevnar             | YES                            | 10                    | 33                  | 33                       | 33                                            | 32              |
| Mabthera            | YES                            | 11                    | 1                   | 1                        | 1                                             | 14              |
| Keppra              | YES                            | 12                    | 21                  | 21                       | 24                                            | 28              |
| Zyprexa             | YES                            | 13                    | 22                  | 22                       | 22                                            | 6               |
| Epxide              | YES                            | 14                    | 5                   | 4                        | 4                                             | 19              |
| Plavix (cardiac)    | YES                            | 15                    | 8                   | 8                        | 5                                             | 10              |
| Growth hormone      | YES                            | 16                    | 14                  | 14                       | 11                                            | 13              |
| Plavix (stroke)     | YES                            | 17                    | 1                   | 1                        | 1                                             | 8               |
| Velcade             | YES                            | 18                    | 4                   | 5                        | 5                                             | 27              |
| Zomera              | NO                             | 26.5                  | 11                  | 11                       | 12                                            | 29              |
| Apo-Go              | NO                             | 26.5                  | 6                   | 6                        | 9                                             | 21              |
| Azilect             | NO                             | 26.5                  | 6                   | 6                        | 9                                             | 17              |
| Cetuximab (Erbitux®) | NO     | 26.5                  | 25                  | 25                       | 25                                            | 31              |
| Dofix               | NO                             | 26.5                  | 15                  | 15                       | 15                                            | 11              |
| Emend               | NO                             | 26.5                  | 25                  | 24                       | 25                                            | 33              |
| Erlotinib (Tarceva®) | NO    | 26.5                  | 25                  | 24                       | 25                                            | 30              |
| Flasodorex          | NO                             | 26.5                  | 11                  | 11                       | 12                                            | 24              |
| Forceto             | NO                             | 26.5                  | 28                  | 28                       | 25                                            | 34              |
| Gardasil            | NO                             | 26.5                  | 9                   | 8                        | 7                                             | 20              |
| Lucentis            | NO                             | 26.5                  | 18                  | 18                       | 15                                            | 18              |
| Rimonabrant (Acomplia®) | NO | 26.5                  | 34                  | 34                       | 34                                            | 25              |
| Sifrol              | NO                             | 26.5                  | 20                  | 20                       | 21                                            | 26              |
| Spiriva             | NO                             | 26.5                  | 29                  | 29                       | 25                                            | 7               |
| Zemplar             | NO                             | 26.5                  | 22                  | 22                       | 22                                            | 15              |
| Zypak               | NO                             | 26.5                  | 24                  | 27                       | 20                                            | 2               |
| Mean rank           | YES                            | 9.5                   | 14.8                | 16.9                     | 16.1                                          | 14.0            |
|                    | NO                             | 26.5                  | 19.3                | 19.2                     | 18.8                                          | 21.4            |

*By international data on cost per QALY gained
rankings derived from the total sample of health policymakers, the physicians and members of the past and present Basket Committees in the sample, and the efficiency ranking according to cost per QALY gained.

Since the Committee did not rank the rejected technologies, we assigned them a value of 26.5, the mean rank of the technologies rejected whatever their actual ranking is (19–34).

According to Table 2, four technologies were rejected by the Committee but ranked relatively high by the DCE: Gardasil and Zyban were ranked between second and fourth, and Apo-Go and Azilect were ranked 12th–14th.
On the other hand, Eloxatin and Xeloda were accepted by the Committee (ranked 5th-6th), but were ranked relatively low (22nd-23rd) by the sample, and Crestor-Ezetrol (1st choice of the Committee) was ranked 22nd-26th by the sample. Growth hormone, an accepted technology ranked 16th by the Committee, was ranked 22nd by the sample. Finally, Plavix prescribed to stroke patients, was ranked 16th by the Committee, but was the first choice of health policy-makers in the sample.

By definition, the mean Committee’s rank of the accepted technologies is 9.5, and that of the rejected ones is 26.5. In the sample of health policy-makers, the corresponding means are 14.8 and 19.3 respectively, indicating that, on the whole, the policy-makers found the accepted technologies less desirable, and the rejected ones – less undesirable. The means among the physicians and those who have ever been members of the Basket Committee in the sample were 16.9 vs. 19.2 and 16.1 vs. 18.8 respectively. The efficiency ranking presents a similar picture, though closer to the Committee’s ranking – the means are 14 and 21.4 respectively.

When the monthly cost threshold increased to 250 NIS (Table 3), four technologies – Plavix (stroke), Gardasil, Emend and Crestor Ezetrol - turned to be characterized by “no” instead of “yes” on the criteria “the technology should be financed publicly so that the poor can use it” (namely, their monthly cost is lower than 250 NIS – but higher than 125 NIS). Their rank dropped considerably: from 1st to 7th, from 9th to 23rd, from 25th to 33rd and from 18th to 28th respectively. Consequently, Lantus Leveimir, a relatively cheap technology advanced from the 29th to the 17th place.

The increased threshold made the Committee’s accepted technologies more desirable by the sample of policy-makers.

Tables 4 and 5 present similar rankings, but for the 18 technologies accepted. In Table 4, the top four technologies accepted by the Committees were ranked 12-15th by the sample. On the other hand, Plavix for stroke patients was ranked 17th by the Committee but was ranked 1st in the sample, and Mabthera – 11th by the Committee and 1st by the sample. Velcade, ranked last (18th) by the Committee, was seen as more desirable (4th-5th) by the sample.

When the monthly cost threshold increased to 250 NIS (Table 5), Plavix (stroke) and Crestor Ezetrol, the two accepted technologies which cost below 250 NIS (but above 125 NID), lost some of their desirability and their ranking dropped from 12th to 15th, and from 1st to 5th respectively.

Tables 6 and 7 present summary measures – correlations - of the joint distributions of the sample’s rankings,

Table 4 The Committee’s and the sample ranking of technologies accepted by the 2006/7 Basket Committee (monthly cost threshold = 125 NIS)

| Technology            | Rank Basket Committee | Rank survey - Total | Rank survey - Physicians | Rank survey - Members of the Basket Committee | Rank efficiency |
|-----------------------|-----------------------|---------------------|--------------------------|-----------------------------------------------|-----------------|
| Crestor Ezetrol       | 1                     | 1                   | 12                       | 12                                            | 10              |
| Atacand Ocsaar Diovan Olmetec | 2      | 2                   | 15                       | 15                                            | 15              |
| Lantus Levermir       | 3                     | 3                   | 15                       | 15                                            | 15              |
| Apidra Humalog Novorapid | 4       | 4                   | 15                       | 15                                            | 15              |
| Eloxatin              | 5                     | 5                   | 10                       | 10                                            | 10              |
| Xeloda                | 6                     | 6                   | 10                       | 10                                            | 10              |
| Herceptin             | 7                     | 7                   | 8                        | 8                                             | 9               |
| Hepsera               | 8                     | 8                   | 3                        | 3                                             | 3               |
| Viread                | 9                     | 9                   | 7                        | 7                                             | 7               |
| Prevnar               | 10                    | 10                  | 18                       | 18                                            | 18              |
| Mabthera              | 11                    | 11                  | 1                        | 1                                             | 1               |
| Keppra                | 12                    | 12                  | 13                       | 13                                            | 14              |
| Zyprexa               | 13                    | 13                  | 14                       | 14                                            | 13              |
| Exjade                | 14                    | 14                  | 5                        | 4                                             | 4               |
| Plavix (cardiac)      | 15                    | 15                  | 6                        | 6                                             | 5               |
| Growth hormon         | 16                    | 16                  | 9                        | 9                                             | 8               |
| Plavix (stroke)       | 17                    | 17                  | 1                        | 1                                             | 1               |
| Velcade               | 18                    | 18                  | 4                        | 5                                             | 5               |

*By international data on cost per QALY gained
the Committee’s ranking and the efficiency ranking of all and accepted technologies respectively, and for the two monthly cost thresholds.

Table 6 presents the correlations for all technologies. Rejected technologies were assigned the mean of 19–34, 26.5. For the 125 and 250 NIS thresholds, the sample’s and the Committee’s rankings are uncorrelated. The correlation between the Committee’s and the efficiency rankings is relatively high and significant (0.45).

Among accepted technologies (Table 7), for both cost thresholds, the sample’s and the Committee’s rankings are relatively highly and significantly negatively correlated. The efficiency ranking is uncorrelated with the sample’s rankings, and correlates (marginally significant) positively with the Committee’s ranking.

Figure 1 portrays the fit of the Committee’s, the total sample’s, and the efficiency rankings graphically. The Figure indicates that, with the two cost thresholds, the lack of fit concentrates in the extremes: the four top and the bottom two technologies of the Committee’s ranking are ranked almost inversely by the sample.

Table 5 The Committee’s and the sample ranking of technologies accepted by the 2006/7 Basket Committee (monthly cost threshold = 250 NIS)

| Technology       | Rank Basket Committee | Rank Diagonal | Rank survey - Total | Rank survey - Physicians | Rank survey - Members of the Basket Committee | Rank efficiency |
|------------------|-----------------------|---------------|---------------------|--------------------------|-----------------------------------------------|-----------------|
| Crestor Ezetrol  | 1                     | 1             | 15                  | 15                       | 15                                            | 9               |
| Atacand Ocsaar Diovan Olmetec | 2                     | 2             | 15                  | 15                       | 15                                            | 2               |
| Lantus Levernir  | 3                     | 3             | 12                  | 12                       | 10                                            | 4               |
| Apidra Humalog Novorapid | 4                    | 4             | 15                  | 15                       | 15                                            | 7               |
| Eloxatin         | 5                     | 5             | 10                  | 10                       | 10                                            | 3               |
| Xeloda           | 6                     | 6             | 10                  | 10                       | 10                                            | 1               |
| Herceptin        | 7                     | 7             | 8                   | 8                        | 9                                             | 15              |
| Hepsera          | 8                     | 8             | 2                   | 2                        | 2                                             | 12              |
| Viread           | 9                     | 9             | 7                   | 5                        | 7                                             | 14              |
| Prevnar          | 10                    | 10            | 18                  | 18                       | 18                                            | 18              |
| Mabthera         | 11                    | 11            | 1                   | 1                        | 1                                             | 11              |
| Keppra           | 12                    | 12            | 13                  | 13                       | 14                                            | 5               |
| Zyprexa          | 13                    | 13            | 14                  | 14                       | 13                                            | 17              |
| Exjade           | 14                    | 14            | 4                   | 3                        | 3                                             | 13              |
| Plavix (cardiac) | 15                    | 15            | 5                   | 5                        | 4                                             | 8               |
| Growth hormon    | 16                    | 16            | 9                   | 9                        | 8                                             | 10              |
| Plavix (stroke)  | 17                    | 17            | 5                   | 5                        | 4                                             | 6               |
| Velcade          | 18                    | 18            | 3                   | 4                        | 4                                             | 16              |

*Significant at 0.05

By international data on cost per QALY gained

Table 6 Correlations among the different rankings: all technologies, monthly cost threshold = 125 and 250 NIS

| Monthly cost threshold = 125 NIS | Rank Basket Committee | Rank survey - Total | Rank survey - Physicians | Rank survey - Members of the Basket Committee | Rank efficiency |
|---------------------------------|-----------------------|---------------------|--------------------------|-----------------------------------------------|-----------------|
| Correlation with the Committee’s ranking - All technologies (survey: 1–34, Committee: NO = 26.5) | 1.000 | 0.035 | 0.036 | 0.096 | 0.450 * |
| Correlation with the Efficiency ranking - All technologies (survey: 1–34, Committee: NO = 26.5) | 0.450 * | 0.067 | 0.040 | 0.176 | 1.000 |

| Monthly cost threshold = 250 NIS | Rank Basket Committee | Rank survey - Total | Rank survey - Physicians | Rank survey - Members of the Basket Committee | Rank efficiency |
|---------------------------------|-----------------------|---------------------|--------------------------|-----------------------------------------------|-----------------|
| Correlation with the Committee’s ranking - All technologies (survey: 1–34, Committee: NO = 26.5) | 1.000 | 0.101 | 0.106 | 0.150 | 0.450 * |
| Correlation with the Efficiency ranking - All technologies (survey: 1–34, Committee: NO = 26.5) | 0.450 * | 0.136 | 0.132 | 0.241 | 1.000 |
Discussion

The prioritization of new technologies submitted for public finance, expected from the Basket Committee, is the most dramatic manifestation of the tension between equity and efficiency considerations in health policy.

We used a recent DCE to predict - based on the stated preferences of Israeli health policy-makers - the desirability of 18 technologies which were accepted by the 2006/7 Basket Committee and 16 which were not.

The results show that, in general, the ranking resulted from the DCE does not agree with the Committee’s inclusion decisions and its ranking. The correlation between the two is null for the entire set of technologies, and negative for the accepted technologies. In particular, the disagreement is pronounced in the two extremes: top technologies accepted by the Committee are ranked 15\textsuperscript{th} (out of 18) by the sample, and the two last technologies ranked 17\textsuperscript{th}-18\textsuperscript{th} by the Committee were ranked 4\textsuperscript{th}-5\textsuperscript{th} by the sample.

Interestingly, the Committee’s inclusion decisions (and to a lesser extent - the ranking of the accepted technologies) are more related to efficiency considerations than to the ranking derived from the preferences of Israeli health policy-makers. As was mentioned earlier, the Israeli health policy-makers tend, at the declarative level, to balance equity and efficiency considerations. It seems that, in general, the members of the Basket Committee tend to prefer efficiency considerations more than health policymakers in general.

Several explanations are suggested. First, the survey’s ranking is based on stated preferences while that of the Committee reflects revealed preferences. Real-
life decisions are complex and involve many dimensions. Real-life prioritizations are based on additional criteria which were not included in the seven presented to the respondents. Furthermore, these criteria might interact in a way that the additive utility construct, which is the basis for DCE, cannot accommodate.

Second, the finding that the Committee's ranking agrees more with the efficiency ranking might be a result of the real budget constraint under which the Committee prioritizes the technologies. Facing a budget constraint, one of the major considerations of the Committee is the budget impact of the technology under consideration (namely, what share of the budget would the technology use if accepted). Since cheap technologies are more likely than expensive ones to have both lower budget impact and to be cost-effective (i.e., to rank high on the efficiency ranking), the Committee's inclusion decision and its ranking are expected to be more correlated with the efficiency ranking than with the survey's, even if the chief efficiency consideration - cost per QALY criterion - is assigned a low weight or even ignored.

A confirmation of these two explanations stems from the comparison of the weights – and hence the ranking – attached to the criteria by health policy-makers who have ever served on a Basket Committee with those of health policy-makers who have not. As in the case of the actual Committee's prioritization, those who have had the experience of “real” deliberations, assign a higher weight to efficiency considerations at the expense of equity ones.

The third possible explanation is related to the fact that some of the Committee's members are “public nominations” rather than policy-makers. However, if the preferences of policy-makers in the Committee are similar to those surveyed, that would mean that the “public nominations” show a higher tendency towards efficiency, which is hardly believable.

Finally, the time gap between the Committee's decisions and ranking and that derived from the survey is almost 10 years. Social norms and values might have changed over the years, leading to differences in the preferences of the Israeli health policy-makers.

Clearly, the task faced by the Committee is not an easy one. However, the existing “guidelines” and “instructions” (issued by the Ministry of Health) for the work of the Committee relate more to the organizational aspects and to the principles to be discussed, rather than trying to provide a more structured framework to the prioritization process, namely, which criteria to be used and what are their relative weights. Consequently, the Committee's decision process is not transparent, hard to be evaluated, unclear and might be inconsistent.

More and more researchers comment on the work of the Israeli Committee and on its decisions [7–12]. Golan and Hansen [12] even propose a decision-support tool based on the principle of “value for money”. The present findings point to the need of health policy-makers in Israel to align and coordinate their decision processes with respect to the equity and efficiency criteria for prioritization and their weights.

Conclusions
The findings presented above indicate that the preferences of the members of the Basket Committee regarding the efficiency-equity tradeoff do not match those of health policy makers. It seems that in real life prioritization facing a budget constraint, health policy makers turn toward efficiency considerations. In order for Israeli health policy to be consistent and well coordinated across policy-makers in various functions, some discussions and exchanges are needed in order to arrive at a common set of preferences with respect to equity and efficiency considerations.

Acknowledgements
Special thanks are due to Ofra Golan for her invaluable contribution.

Funding
This study was financed by a grant from the Israeli National Institute for Health Policy Research.

Availability of data and materials
Data will not be shared at the moment since the authors have not completed its analysis.

Competing interests
The author declares that he has no competing interests.

Ethics approval and consent to participate
The study was approved by the Ethics Committee of the Faculty of Social Sciences of the Hebrew University of Jerusalem.

Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Received: 31 December 2015 Accepted: 29 March 2017
Published online: 30 April 2017

References
1. Guyer AJ. The bogus conflict between efficiency and vertical equity. Health Econ. 2006;15:1153–8.
2. Williams A, Tsuchiya A, Dolan P. Eliciting equity efficiency trade-offs in health. In: Smith P, Ginnelly L, Sculpter M, editors. Health policy and economics: opportunities and challenges. Maidenhead: Open University Press; 2005. p. 64–87.
3. Israeli Ministry of Health. The Procedure of Updating the Health Services Basket – February 2010. 2011, [Hebrew] Jerusalem, [http://www.health.gov.il/hozer/sal_noal181010.pdf]
4. Shmueli A. Economic evaluation of the decisions of the Israeli public committee for updating the national list of health services in 2006/7. Value Health. 2009;12:202–6.
5. Shmueli A, Golan O, Paolucci F, and Mentzakis E. Efficiency and equity considerations in the preferences of health policy-makers in Israel. Israel Journal of Health Policy Research. 2017. doi:10.1186/s13584-017-0142-7.
6. Mirelman A, Mentzakis E, Kinter E, et al. Decision making criteria among national policy-makers in five countries: a discrete choice experiment eliciting relative preferences for equity and efficiency. Value Health. 2012;15:534–9.
7. Greenberg D, Siebzehner MI, Pliskin JS. The process of updating the National List of Health Services in Israel: Is it legitimate? Is it fair? Int J Technol Assess Health Care. 2009;25:255–61.
8. Israeli A, Chinitz D. Updating the basket of health services [Hebrew]. Harefuah. 2003;142:100–2.
9. Chinitz D, Shalev C, Galai N, Israeli A. The second phase of priority setting. Israel’s basic basket of health services: the importance of being explicitly implicit. BMJ. 1998;317:1005–7.
10. Shani S, Yahalom Z. The Israeli model for managing the national list of health services in an era of limited resources. Law Policy. 2002;24:133–47. doi:10.1111/1467-9930.00131.
11. Golan O, Hansen P, Kaplan G, Tal O. Health technology prioritization: which criteria for prioritizing new technologies and what are their relative weights? Health Policy. 2011;102:26–35.
12. Golan O and Hansen P., Which health technologies should be funded? A prioritization framework based explicitly on value for money. Israel J Health Policy Res 2012;1:44 doi: 10.1186/2045-4015-1-44